# Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma

> **NCT03639467** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 40 (estimated)

## Conditions studied

- Recurrent Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Anlotinib plus gemcitabine/cisplatin

## Key facts

- **NCT ID:** NCT03639467
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-18
- **Primary completion:** 2021-08-22
- **Final completion:** 2023-08-15
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03639467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03639467, "Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03639467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*